Illumina illegally monopolised DNA sequencing market, rival says
Shutterstock/Sundry Photography
Illumina obtained monopoly power over the market for next-generation DNA sequencing by concealing information from the US Patent and Trademark Office (USPTO) and through sham patent litigation, a rival company has alleged.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Subscribe now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10